Fig. 4.
Novel antibody labeling on liver NPCs is distinct from that of previously reported antibodies. (A,D,G) Negative controls indicate labeling with isotype control antibodies. Examples of comparative labeling with the antibodies described here and (B,C) Sca-1, (E,F) CD26/DPPIV, or (H) EpCAM are shown. EpCAM versus OC2-1D11 labeling is shown for (G,H) NPCs from untreated liver, whereas (A–F) the Sca-1 and CD26 comparisons used DDC-treated NPCs.